Research Analysts Set Expectations for CNTX FY2024 Earnings

Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Research analysts at HC Wainwright dropped their FY2024 earnings estimates for shares of Context Therapeutics in a research report issued on Thursday, November 7th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.53) per share for the year, down from their previous estimate of ($0.52). HC Wainwright has a "Buy" rating and a $6.00 price objective on the stock. The consensus estimate for Context Therapeutics' current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Context Therapeutics' Q4 2024 earnings at ($0.04) EPS, FY2025 earnings at ($0.37) EPS, FY2026 earnings at ($0.52) EPS and FY2027 earnings at ($0.64) EPS.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.11).

Context Therapeutics Stock Up 5.6 %

CNTX traded up $0.11 during midday trading on Monday, hitting $2.06. 67,370 shares of the company traded hands, compared to its average volume of 308,541. The firm has a market capitalization of $154.47 million, a PE ratio of -2.25 and a beta of 2.25. The company's 50-day moving average is $2.09 and its 200 day moving average is $2.07. Context Therapeutics has a 52 week low of $0.77 and a 52 week high of $2.75.

Institutional Investors Weigh In On Context Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC increased its position in shares of Context Therapeutics by 63.4% during the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company's stock valued at $131,000 after purchasing an additional 25,300 shares during the last quarter. Opaleye Management Inc. increased its holdings in Context Therapeutics by 13.7% in the 1st quarter. Opaleye Management Inc. now owns 1,108,357 shares of the company's stock worth $1,530,000 after acquiring an additional 133,357 shares in the last quarter. Affinity Asset Advisors LLC increased its holdings in Context Therapeutics by 392.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company's stock worth $3,246,000 after acquiring an additional 1,290,323 shares in the last quarter. Ally Bridge Group NY LLC increased its holdings in Context Therapeutics by 159.8% in the 2nd quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company's stock worth $3,782,000 after acquiring an additional 1,160,281 shares in the last quarter. Finally, Nantahala Capital Management LLC purchased a new stake in Context Therapeutics in the 2nd quarter worth approximately $3,881,000. Hedge funds and other institutional investors own 14.03% of the company's stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.